The Women's Health Initiative reports in perspective: Facts or fallacies?

Climacteric

Volumn 7, Issue 3, 2004, Pages 225-228

  Don Gambrell Jr , R ^a,b  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b Reproductive Endocrinologists   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; PROGESTERONE;

ADULT; AGED; BONE DISEASE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; COLON CANCER; DYSPAREUNIA; ESTROGEN THERAPY; FEMALE; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HEALTH PROGRAM; HORMONAL THERAPY; HUMAN; MASS MEDIUM; MENOPAUSAL SYNDROME; MORTALITY; PRIORITY JOURNAL; REVIEW; VAGINA ATROPHY; VAGINA DRYNESS; VAGINITIS; VULVA DISEASE; WOMEN HEALTH INITIATIVE;

AGE FACTORS; AGED; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; COLORECTAL NEOPLASMS; DATA INTERPRETATION, STATISTICAL; DEMENTIA; ESTROGEN REPLACEMENT THERAPY; FEMALE; HIP FRACTURES; HUMANS; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; RISK FACTORS; WOMEN'S HEALTH;

EID: 4944225435     PISSN: 13697137     EISSN: None     Source Type: Journal    
DOI: 10.1080/13697130400001349     Document Type: Review

References (14)

1. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288:321-3
2. Strickler RC. Women's Health Initiative results: a glass more empty than full. Fertil Steril 2003;80:488-90
3. Hersh AL, Stefanik ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. J Am Med Assoc 2004;291:47-53
4. Position Statement. Estrogen and progestogen use in peri- and postmenopausal women. September 2003 position paper of The North American Menopause Society. Menopause 2003;10:497-506
5. Schneider HPG. The view of The International Menopausal Society on The Women's Health Initiative. Climacteric 2002;5:211-16
6. Notelovitz M. Editorial: The clinical practice impact of The Women's Health Initiative: political vs biologic correctness. Maturitas 2003;44:3-9
7. Gambrell RD Jr, Utian WH. (Letter to Editor and Reply) Menopause 2004;11:236-7
8. Yates J, Barrett-Conner E, Barlas S, et al. Rapid loss of hip fracture protection after estrogen cessation: evidence from the National Osteoporosis risk assessment. Obstet Gynecol 2004;103:440-6
9. The Women's Health Initiative Steering Committee. Effect of conjugated equine estrogens in postmenopausal women with hysterectomy. J Am Med Assoc 2004;291:1701-12
10. Hully S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998;280:605-13
11. Anderson GL, Judd HL, Kaunitz AM, et al. Effect of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. J Am Med Assoc 2003:290:1739-48
12. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047-59
13. Zandi PP, Carlson MC, Plassman BL, et al. Hormone replacement therapy and incidence of Alzheimer disease in older women. J Am Med Assoc 2002;288:2123-9
14. Speroff L. A clinician demurs. Sexuality, Reproduction, and Menopause 2003;1:15-18